Actinogen Medical Limited (ATGGF)

OTHER OTC:ATGGF

ATGGF

Actinogen Medical

RESEARCH TOOLSreports

Actinogen Medical (ATGGF) Price & Analysis

25 Followers

ATGGF Stock Chart & Stats

$0.03

$0.00(0.00%)

At close: Nov 27 4:00 PM EST

$0.03

$0.00(0.00%)

Day’s Range― - ―

52-Week Range$0.01 - $1.00

Previous CloseN/A

Volume684.50K

Average Volume (3M)1.75K

Market Cap

$95.49M

Enterprise Value$130.21M

Total Cash (Recent Filing)$6.53M

Total Debt (Recent Filing)$366.31K

Price to Earnings (P/E)―

Beta-6.51

Next Earnings

Aug 31, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding3,657,944,300

10 Day Avg. Volume5,000

30 Day Avg. Volume1,750

Financial Highlights & Ratios

PEG Ratio0.25

Price to Book (P/B)3.74

Price to Sales (P/S)12.48

P/FCF Ratio-9.03

Enterprise Value/Market Cap1.36

Enterprise Value/Revenue23.72

Enterprise Value/Gross Profit24.67

Enterprise Value/Ebitda-6.55

Forecast

1Y Price Target

$0.06

Price Target Upside90.14% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)>-0.01

Revenue Forecast (FY)$3.93M

Bulls Say, Bears Say

Bulls Say

Low Leverage / Healthy Equity PositionLow leverage gives the company durable financial flexibility during multi-year clinical programs. With limited debt service obligations, management can prioritize R&D and trial timelines, reducing short-term refinancing risk and preserving capacity to fund operations via equity or partnerships.

Focused Clinical-stage Lead Asset (Xanamem)A single, well-defined lead asset addressing multiple CNS indications concentrates resources and creates clear milestone pathways. A differentiated mechanism (11β-HSD1 inhibition) and dual-indication development raise the program's strategic value for licensing or partnering, supporting long-term optionality.

High Gross Margin Profile ReportedA reported 100% gross margin (typical for clinical-stage biotechs) implies low COGS and strong long-term margin potential post-launch. If Xanamem achieves approval, the business model could scale with high incremental margins, supporting sustainable profitability and cash generation.

Bears Say

Sharply Declining RevenueA substantial revenue decline erodes internal funding alternatives and signals limited current commercial traction. Over a 2–6 month horizon this weakens the company's ability to self-fund development, increases dependence on external financing, and constrains investments in trials or partnering activities.

Negative Operating And Free Cash FlowPersistent negative operating and free cash flow, with worsening free cash flow growth, creates a structural financing gap for ongoing clinical programs. This raises the likelihood of dilutive capital raises, potential delays to development milestones, and weaker negotiating leverage with partners.

Reliance On Capital Raises; No Recurring Commercial RevenueDependence on equity financings and the absence of commercial revenue is a persistent structural risk for clinical-stage biotech. It exposes shareholders to dilution, ties progress to capital market access, and forces management to prioritize financing events over long-term strategic choices if market conditions tighten.

Actinogen Medical News

Actinogen wins aligned EMA and FDA backing for Xanamem Alzheimer’s path

An announcement from Actinogen Medical ( ($AU:ACW) ) is now available. Actinogen Medical has secured positive scientific advice...

9d ago

Actinogen Medical Seeks ASX Quotation for 66.7 Million New Shares

Actinogen Medical ( ($AU:ACW) ) just unveiled an update. Actinogen Medical has applied to the ASX for quotation...

16d ago

Actinogen convenes June shareholder meeting as Xanamem trials advance

The latest announcement is out from Actinogen Medical ( ($AU:ACW) ). Actinogen Medical has called a general meeting...

16d ago

Actinogen CEO Exercises Options as Key Alzheimer’s Trial Milestone Nears

Actinogen Medical ( ($AU:ACW) ) has shared an announcement. Actinogen Medical has highlighted that two tranches of unlisted...

24d ago

Actinogen CEO Steven Gourlay Boosts Shareholding Through Option Exercise

Actinogen Medical ( ($AU:ACW) ) just unveiled an update. Actinogen Medical has disclosed a change in director Dr...

24d ago

Actinogen Medical Seeks ASX Quotation for 2.44m New Shares

Actinogen Medical ( ($AU:ACW) ) has issued an update. Actinogen Medical Limited, an Australian biotechnology company listed on...

24d ago

Actinogen Seeks ASX Quotation for 60,000 New Shares

Actinogen Medical ( ($AU:ACW) ) has issued an announcement. Actinogen Medical Limited has applied to the ASX for...

26d ago

Actinogen cancels 2.8m shares under employee scheme buy-back

Actinogen Medical ( ($AU:ACW) ) has issued an announcement. Actinogen Medical has notified the market of the cessation...

1M ago

Actinogen extends cash runway as pivotal Alzheimer’s trial advances

Actinogen Medical ( ($AU:ACW) ) has shared an announcement. Actinogen Medical reported progress on its pivotal XanaMIA phase...

1M ago

Actinogen extends cash runway as pivotal Alzheimer’s trial advances

Actinogen Medical ( ($AU:ACW) ) has provided an announcement. Actinogen Medical reported steady progress in its pivotal XanaMIA...

1M ago

ATGGF FAQ

What was Actinogen Medical Limited’s price range in the past 12 months?

Actinogen Medical Limited lowest stock price was $0.01 and its highest was $1.00 in the past 12 months.

What is Actinogen Medical Limited’s market cap?

Actinogen Medical Limited’s market cap is $95.49M.

When is Actinogen Medical Limited’s upcoming earnings report date?

Actinogen Medical Limited’s upcoming earnings report date is Aug 31, 2026 which is in 86 days.

How were Actinogen Medical Limited’s earnings last quarter?

Actinogen Medical Limited released its earnings results on Feb 25, 2026. The company reported -$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.003.

Is Actinogen Medical Limited overvalued?

According to Wall Street analysts Actinogen Medical Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Actinogen Medical Limited pay dividends?

Actinogen Medical Limited does not currently pay dividends.

What is Actinogen Medical Limited’s EPS estimate?

Actinogen Medical Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Actinogen Medical Limited have?

Actinogen Medical Limited has 3,657,944,300 shares outstanding.

What happened to Actinogen Medical Limited’s price movement after its last earnings report?

Actinogen Medical Limited reported an EPS of -$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Actinogen Medical Limited?

Currently, no hedge funds are holding shares in ATGGF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Actinogen Medical Stock Smart Score

Outperform

Fundamentals

Return on Equity

-134.14%

Trailing 12-Months

Asset Growth

-55.10%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Actinogen Medical Limited

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It is developing Xanamem, an inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials that achieves target engagement in the central nervous system, Alzheimer's disease, depression with cognitive impairment, and anxiety, sleep, and behavioral problems in fragile X syndrome. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.

Actinogen Medical (ATGGF) Earnings & Revenues

Historic Earnings Reports

ATGGF Stock 12 Month Forecast

Average Price Target

$0.06

▲(90.14% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","-1":"-$1","-0.5":"-$0.5","0.5":"$0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.0570432,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$0.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.0570432,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$0.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.0570432,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.06</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.031,0.03300332307692308,0.03500664615384615,0.037009969230769234,0.03901329230769231,0.04101661538461539,0.04301993846153847,0.04502326153846154,0.047026584615384615,0.049029907692307695,0.051033230769230775,0.05303655384615385,0.05503987692307693,{"y":0.0570432,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.031,0.03300332307692308,0.03500664615384615,0.037009969230769234,0.03901329230769231,0.04101661538461539,0.04301993846153847,0.04502326153846154,0.047026584615384615,0.049029907692307695,0.051033230769230775,0.05303655384615385,0.05503987692307693,{"y":0.0570432,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.031,0.03300332307692308,0.03500664615384615,0.037009969230769234,0.03901329230769231,0.04101661538461539,0.04301993846153847,0.04502326153846154,0.047026584615384615,0.049029907692307695,0.051033230769230775,0.05303655384615385,0.05503987692307693,{"y":0.0570432,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.01,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.02,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.025,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.025,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.025,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.025,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.04,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.04,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.031,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.031,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.031,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.031,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.031,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >